2025-12-30 - Analysis Report
Okay, here's a breakdown of the provided information for Recursion Pharmaceuticals (RXRX), followed by an overall analysis.

**1) Performance vs. S&P 500 (VOO)**

*   **RXRX:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging AI and machine learning to discover and develop novel therapeutics.
*   **RXRX Cumulative Return:** -31.19%
*   **VOO Cumulative Return:** 45.19%
*   **Divergence:** -73.9
*   **Relative Divergence:** 0.3

**Analysis:** RXRX has significantly underperformed the S&P 500. The divergence of -73.9 indicates substantial underperformance, and the relative divergence of 0.3 suggests the current divergence is near the lower end of its historical range.

**Alpha, Beta Analysis Table:**

| Year      | CAGR  | MDD   | Alpha | Beta  | Cap(B) |
|-----------|-------|-------|-------|-------|--------|
| 2021-2023 | 22.0% | 81.0% | 26.0% | -0.2  | 5.0    |
| 2022-2024 | 11.0% | 81.0% | -10.0% | 0.1   | 3.4    |
| 2023-2025 | 11.0% | 80.0% | -56.0% | 0.1   | 2.1    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) has decreased over the three periods.
*   **MDD:** Maximum Drawdown is consistently high, showing significant volatility.
*   **Alpha:** Alpha has decreased significantly over time from 26% to -56%, indicating a decreasing ability to outperform the market on a risk-adjusted basis.
*   **Beta:** Beta is relatively low and close to zero, suggesting RXRX's price is not strongly correlated with the overall market. A negative beta in 2021-2023 indicates RXRX moved opposite to the market in that period.
*   **Cap:** Market capitalization has decreased.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 4.25
*   **Last Market Data:** Price: 4.13, Previous Close: 4.25, Change: -2.82%
*   **5-day SMA:** 4.334
*   **20-day SMA:** 4.5043
*   **60-day SMA:** 4.9864

**Analysis:** The stock is trading below all its short-term and medium-term moving averages (5, 20, and 60-day SMA), indicating a recent downward trend. The most recent trading day also shows a price decrease compared to the previous close.

**3) RSI, PPO, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 38.50
*   **PPO:** -0.0178
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (225 shares - Very Safe - MRI:0.90) Monthly invest 1.7% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) Relative Divergence Change:** -0.5 (Downward Trend)
*   **Expected Return (%):** -552.1%

**Analysis:**

*   **MRI:** The high MRI score (0.9) suggests, according to this indicator, that it's a good time to invest, but this should be considered in light of other indicators.
*   **RSI:** The RSI is below 40, suggesting the stock is nearing oversold conditions, potentially signaling a possible bounce.
*   **PPO:** The negative PPO indicates the short-term moving average is below the long-term moving average, signaling a downward trend.
*   **Hybrid Signal:** Recommends buying the stock, but considers the high MRI score, which might conflict with other indicators.
*   **Recent Divergence Change:** Confirms the recent downward trend compared to the S&P 500.
*   **Expected Return:** The extremely negative expected return suggests very poor long-term prospects based on this model.

**4) Recent News & Significant Events**

*   **Bullish catalysts:** Analyst Upgrade (JPMorgan), Positive trial data (REC-4881), ARK Buying.
*   **CEO Transition:** Transition announced.
*   **Negative Sentiment:** Cramer calls it "Speculative."

**Analysis:** Recent news presents a mixed picture. While there are positive catalysts like analyst upgrades and positive trial data, Jim Cramer's comment paints the stock as a high-risk investment. The announcement of a CEO transition can also create uncertainty.

**4-2) Analyst Opinions**

*   **Consensus:** Hold (2.5 on a 1-5 scale)
*   **Opinions:** 7 Analysts
*   **Target Price:** Average: $7.00, High: $11.00, Low: $3.00

**Analysis:** The analyst consensus is "Hold," suggesting a neutral outlook on the stock. The average target price of $7.00 is significantly higher than the current price, but there is a wide range ($3.00 - $11.00), indicating uncertainty among analysts. The lack of recent rating changes information makes it difficult to know if the analyst estimates are consistent with the most recent developments.

**5) Recent Earnings Analysis**

| Date       | EPS   | Revenue    |
|------------|-------|------------|
| 2025-11-05 | -0.36 | $0.01B     |
| 2025-08-05 | -0.41 | $0.02B     |
| 2025-05-05 | -0.50 | $0.01B     |
| 2024-11-06 | -0.34 | $0.03B     |
| 2025-11-05 | -0.34 | $0.03B     |

**Analysis:** The company is consistently losing money (negative EPS). While revenue fluctuates, it remains relatively low. The EPS is fluctuating but appears to have some improvement recently.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-09-30 | $0.00B    | -194.74%      |
| 2025-06-30 | $0.02B    | -5.54%        |
| 2025-03-31 | $0.01B    | -47.31%       |
| 2024-12-31 | $0.00B    | -183.62%      |
| 2024-09-30 | $0.03B    | 53.69%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE       |
|------------|----------|-----------|
| 2025-09-30 | $1.05B   | -15.50%   |
| 2025-06-30 | $0.92B   | -18.70%   |
| 2025-03-31 | $0.93B   | -21.68%   |
| 2024-12-31 | $1.03B   | -17.29%   |
| 2024-09-30 | $0.52B   | -18.27%   |

**Analysis:** The company's revenue is inconsistent and low. Profit margins are mostly negative, indicating a struggle to generate profit. Equity is relatively high, but ROE (Return on Equity) is negative, signifying that the company is not generating profits from shareholders' investments.

**7) Comprehensive Analysis (Summary)**

RXRX is a high-risk, high-potential-reward stock. It has significantly underperformed the S&P 500, and its financial performance is weak.

*   **Negatives:**
    *   Significant underperformance compared to the market.
    *   High volatility (high MDD).
    *   Negative and declining Alpha.
    *   Consistently negative EPS and ROE.
    *   Inconsistent and low revenue.
    *   Recent downward price trend.
    *   High negative expected return.
*   **Positives/Potential Catalysts:**
    *   Analyst upgrades.
    *   Positive trial data.
    *   High Market Risk Indicator (MRI).
    *   Potentially oversold RSI.
    *   Significant cash on the balance sheet (as indicated by the large Equity).
    *   AI application is a potentially valuable area

**Overall Assessment:** RXRX is a speculative investment. Investors should weigh the significant risks against the potential for high returns based on its AI platform and drug development pipeline. The negative financial metrics and underperformance should be carefully considered. A turnaround relies heavily on successful clinical trials and ultimately generating revenue.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.